P/B
15,6
Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
$40.7B
Market Cap • 10/9/2026
2014
(12 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
12,2
EPS
—
Market Cap
Market Cap
40,7B
EV
37,4B
EV/Revenue
0
EV/EBITDA
-23,1
EV/EBIT
-23
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5,6%
Total Yield
-5,6%
Payout
0%
Retained Earnings
-4B
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
80,5%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
3,8%
% Goodwill
0,3%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
62,5%
CAGR Net Income 5Y
65,4%
CAGR EPS 5Y
33,6%
CAGR OCF 5Y
58,2%
Leverage
N.D./EBITDA
2
Debt/Equity
0%
Current Ratio
11,4
Quick Ratio
11,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!